What is BioSilta?
BioSilta Oy is a biotechnology firm specializing in innovative solutions for biomanufacturing and therapeutic development. The company's core offerings include the EnPresso B growth systems designed for optimizing bacterial cultures and advanced glycosylation techniques aimed at enhancing the therapeutic potential of glycoproteins, such as monoclonal antibodies. By focusing on biochemical modifications, BioSilta seeks to improve protein functionality and stability, positioning itself at the forefront of glycan biology research and its applications in modern medicine.
How much funding has BioSilta raised?
BioSilta has raised a total of $3.4M across 1 funding round:
Unspecified
$3.4M
Unspecified (2014): $3.4M with participation from Inveni Capital and Omega Funds
Key Investors in BioSilta
Inveni Capital
Inveni Capital is a European venture capital fund focused on climate technology, investing in startups that prioritize environmental impact and sustainable solutions.
Omega Funds
Omega Funds is a venture capital firm with a primary investment focus on drug discovery and development companies within the life science and healthcare sectors.
What's next for BioSilta?
With the recent major strategic investment, BioSilta Oy is poised for accelerated growth and further innovation in its specialized biotechnology fields. The substantial capital infusion is expected to fuel advancements in their EnPresso B growth systems and expand their research into enhancing therapeutic glycoproteins. This strategic backing suggests a move towards scaling operations and potentially commercializing their cutting-edge biotechnological solutions, solidifying their position in the competitive biomanufacturing and biopharmaceutical markets.
See full BioSilta company page
